Typicality: | 0.577 |
Saliency: | 0.500 |
after human trial | 11 | temporal |
in 2002 | 7 | temporal |
each year | 6 | temporal |
drug → enter → the market | 113 |
drug → be entered → the market | 6 |
drug → enter → market | 3 |
drug → entered → the market | 3 |
drug → enter into → the market | 3 |
negative | neutral | positive |
0.242 | 0.612 | 0.146 |
Raw frequency | 128 |
Normalized frequency | 0.500 |
Modifier score | 0.850 |
Perplexity | 310.023 |